Global Anti-suicide Drugs Market - 2024-2031

Report Overview

Global Anti-Suicide Drugs Market reached US$ 97.2 billion in 2023 and is expected to reach US$ 136.4 billion by 2031, growing at a CAGR of 4.5% during the forecast period 2024-2031.

Anti-suicide drugs serve as a therapy for preventing suicidal thoughts and attempts. However, the drug needs to be administered under the direction of a physician as overdosing on these drugs can be fatal. These drugs help in reducing the symptoms of depression and other mental illnesses that can trigger suicidal thoughts.

These drugs help manage anxiety, which can be a contributing factor to suicidal ideation. Mood stabilizers are used to manage the highs and lows of bipolar disorder, reducing the risk of suicidal behavior during depressive episodes.

Market Dynamics: Drivers & Restraints

The rising number of depression disorders

The rising number of depression disorders is expected to drive the market growth. As the number of depression disorders rises, the demand for effective treatment alternatives, including anti-suicide medications increases. This expanding patient population increases demand for a wide range of medications.

The increase in depression disorders raises the necessity of suicide prevention, which motivates the development and usage of anti-suicide medications. Efforts to lower suicide rates and enhance mental health outcomes result in greater investment in research and treatment alternatives.

For instance, according to the report by the World Health Organization in 2023, an estimated 3.8% of the population experience depression, including 5% of adults, and 5.7% of adults older than 60 years. Approximately 280 million people in the world have depression.

Depression is about 50% more common among women than among men. Worldwide, more than 10% of pregnant women and women who have just given birth experience depression. Thus, the increasing number of individuals with depression disorders increases the demand for anti-suicide drugs which further drives the market growth.

Regulatory Challenges

Delays in the commercialization of drugs can occur from lengthy approval processes caused by strict regulatory requirements for clinical research and information submissions. Pharma companies suffer from an increased financial burden as they have to conduct lengthy and expensive clinical trials to meet regulatory standards. Thus, the above factors could hamper the market growth.

Market Segment Analysis

The global anti-suicide drugs market is segmented based on drug class, distribution channel, and region.

The anti-depressants & anti-anxiety drugs segment is expected to dominate the market share

Anti-depressants and anti-anxiety drugs hold a significant portion of the market share and are expected to continue throughout the forecast period due to their proven effectiveness in treating symptoms of depression and anxiety, both of which are key factors in having thoughts of suicide. These drugs are often employed as a primary treatment, helping to stabilize mood and minimize thoughts of suicide.

Their established clinical use and continuous research into their effectiveness position them significantly in the market's growth and development. The anti-depressant and anti-anxiety medications category is likely to keep a strong position in the anti-suicide drugs market because of their vital role in dealing with primary mental health.

Market Geographical Analysis

North America is expected to hold a significant position in the anti-suicide drugs market share

North America is the dominant share in the global anti-suicide drugs market, and it is primarily attributed to factors such as rising incidences of suicidal cases and launching a wide range of anti-suicidal drugs. The region has well-established healthcare systems and advanced clinical research facilities, allowing for the development and distribution of novel anti-suicide drugs.

For instance, on September 28, 2023, Fabre-Kramer Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for Exxua for the treatment of major depressive disorder (MDD) in adults. EXXUA is the first truly selective agonist of the serotonin 1a receptor that has been consistently linked to the mediation of mood disorders and suicide risk.

Moreover, the established healthcare infrastructure, rising disposable income, and higher investment in R&D activities contribute to North America's share growth. Thus, the above factors are expected to hold the region in the dominant position.

Market Segmentation

By Drug Class

• Anti-Depressants & Anti-Anxiety Drugs
• Anti-Psychotic Drugs
• NMDA Antagonist
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the market include Eli Lilly and Company, GSK Plc, H. Lundbeck A/S, Pfizer Inc., Teva UK Limited, Organon International, Johnson & Johnson Services Inc., and Allergan Inc. among others.

Why Purchase the Report?

• To visualize the global anti-suicide drugs market segmentation based on drug class, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of anti-suicide drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global anti-suicide drugs market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies